Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results.
The objective of this study is to assess the efficacy of ICRF-187 as a protective agent against anthracycline cardiotoxicity. Cardiac function was evaluated by echocardiography before and after each cycle of anthracycline chemotherapy associated with ICRF-187 and compared with that of a second group receiving anthracycline chemotherapy without ICRF-187. The patients were a group of 15 consecutive children affected with various types of solid tumors who were treated with either doxorubicin-daunomycin or epirubicin (average doses 340 and 280 mg/m2, respectively), and treatment was associated with ICRF-187. A second group of 15 consecutive children affected with different malignancies were simultaneously treated with either doxorubicin-daunomycin or epirubicin (average doses 309 and 270 mg/m2, respectively), but without ICRF-187 association. None of the patients treated with anthracyclines and ICRF-187 association showed abnormalities on echocardiographic examination. In the second group of patients treated with anthracyclines but without ICRF-187 association, we observed a decrease in the left ventricular ejection fraction to < 55% and a decrease in the left ventricular fractional shortening to < 28% in two patients (13.3%). One of these (6.6%) showed a dilatative cardiomyopathy. Both groups of patients were treated with low doses of anthracyclines. Although this study was not randomized, in patients without ICRF-87 cardioprotection, there was a trend for a worse evolution with one case of clinical cardiomyopathy as well as subclinical cardiac abnormalities.
Schiavetti
A
A
Department of Pediatrics, University La Sapienza, Rome, Italy.
Castello
M A
MA
Versacci
P
P
Varrasso
G
G
Padula
A
A
Ventriglia
F
F
Werner
B
B
Colloridi
V
V
D000293:Adolescent; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use / Q000633:toxicity*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002319:Cardiovascular System / Q000187:drug effects* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin / Q000627:therapeutic use / Q000633:toxicity; D004317:Doxorubicin / Q000627:therapeutic use / Q000633:toxicity; D004347:Drug Interactions; D015251:Epirubicin / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D011929:Razoxane / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D015251:Epirubicin; D011929:Razoxane; D004317:Doxorubicin; D003630:Daunorubicin